Development of a Phase 3 protocol for the study of reproduced drugs

20 December 2020

CPD has started developing a Phase 3 protocol for the study of reproduced drugs used for non-inhalation anesthesia.

A phase I study of an innovative drug used in the treatment of patients with a new coronavirus infection (COVID-19) has been completed. The final report has been prepared.

CPD has developed a strategy for preclinical and clinical study of a new prolonged finished dosage form in order to further obtain a registration certificate.

Subscribe to the newsletter of interesting articles and news

Devel­op­ment of a Phase 3 protocol for the study of repro­duced drugs

Development of a Phase 3 protocol for the study of reproduced drugs